Please login to the form below

Not currently logged in
Email:
Password:

Gedeon Richter strengthens its biotechnology business

Gedeon Richter, and Helm, its German partner, have purchased Strathmann Biotec for EUR 22.9m to expand both companies' biotechnology research activities

Hungary-based generics manufacturer, Gedeon Richter, and Helm, its German partner, have purchased German-headquartered Strathmann Biotec for EUR 22.9m to expand both companies biotechnology research activities.

The joint venture will be 70 per cent owned by Gedeon Richter, with Helm holding the remaining 30 per cent. The deal is subjected to regulatory approval.

Strathmann Biotec has a biotechnology plant for bacterial biotechnology, as well as an R&D laboratory and pilot plant capacity. The company employs 81 staff.

Gedeon Richter says that its strategic goal is to establish a strong biopharmaceutical line to expand its worldwide product portfolio by offering products with high added value.

16th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics